Amanda Axtman

Cancer Therapy : Preclinical Pretargeted Radioimmunotherapy Using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma

P. Stayton, J. Pagel, F. Buchegger, 2011 .

Pretargeted Radioimmunotherapy Using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma

P. Stayton, J. Pagel, F. Buchegger, 2011, Clinical Cancer Research.

Title : Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma

S. Wilbur, P. Stayton, F. Buchegger, 2022 .

Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model.

F. Appelbaum, J. Pagel, D. Hamlin, 2011, Blood.

Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.

J. Pagel, D. Hamlin, D. Wilbur, 2010, Blood.